MRTX +32% in sympathy with AMGN’s ASCO presentation on AMG-510: https://finance.yahoo.com/news/amgen-drug-shows-high-response-151127367.html https://finance.yahoo.com/news/amgen-announces-first-clinical-data-130000736.html AMGN itself was +3% today. ARRY, who licensed MRTX849 to MRTX, was +6%.